Free Trial
NASDAQ:BBOT

BridgeBio Oncology Therapeutics (BBOT) Stock Price, News & Analysis

BridgeBio Oncology Therapeutics logo
$2.02 -0.12 (-5.37%)
As of 11:29 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About BridgeBio Oncology Therapeutics Stock (NASDAQ:BBOT)

Advanced

Key Stats

Today's Range
$2.00
▼
$2.23
50-Day Range
$2.04
▼
$8.98
52-Week Range
$1.98
▼
$14.87
Volume
260,944 shs
Average Volume
433,338 shs
Market Capitalization
$162.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.33
Consensus Rating
Moderate Buy

Company Overview

BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted treatments for cancers driven by RAS and related signaling pathways. The company’s research centers on disrupting molecular signals that help cancer cells grow and survive.

Its development programs include drug candidates designed to target KRAS mutations and interactions between RAS and other cancer-related proteins. These investigational medicines are being studied for potential use in solid tumors; they are not approved treatments.

BridgeBio Oncology Therapeutics emerged from BridgeBio Pharma’s oncology business. Its work includes drug development and clinical research, with programs aimed at addressing cancers for which existing targeted treatment options remain limited.

AI Generated. May Contain Errors.

BridgeBio Oncology Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

BBOT MarketRank™: 
3.81657590649 of 5 stars

BridgeBio Oncology Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 122nd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BridgeBio Oncology Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    BridgeBio Oncology Therapeutics has a consensus price target of $19.33, representing about 803.4% upside from its current price of $2.14.

  • Amount of Analyst Coverage

    BridgeBio Oncology Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about BridgeBio Oncology Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for BridgeBio Oncology Therapeutics are expected to grow in the coming year, from ($2.75) to ($2.50) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BridgeBio Oncology Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BridgeBio Oncology Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BridgeBio Oncology Therapeutics has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.72% of the float of BridgeBio Oncology Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    BridgeBio Oncology Therapeutics has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in BridgeBio Oncology Therapeutics has recently decreased by 9.82%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    BridgeBio Oncology Therapeutics does not currently pay a dividend.

  • Dividend Growth

    BridgeBio Oncology Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    BridgeBio Oncology Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for BridgeBio Oncology Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 3 people have searched for BBOT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added BridgeBio Oncology Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BridgeBio Oncology Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    24.40% of the stock of BridgeBio Oncology Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    54.89% of the stock of BridgeBio Oncology Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about BridgeBio Oncology Therapeutics' insider trading history.
Receive BBOT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BridgeBio Oncology Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BBOT Stock News Headlines

My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
See More Headlines

BBOT Stock Analysis - Frequently Asked Questions

BridgeBio Oncology Therapeutics' stock was trading at $11.50 on January 1st, 2026. Since then, BBOT shares have decreased by 81.4% and is now trading at $2.14.

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) released its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.43) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.22.

BridgeBio Oncology Therapeutics' top institutional investors include Regents of The University of California (3.13%), State Street Corp (1.11%), Marshall Wace LLP (0.60%) and Palumbo Wealth Management LLC (0.12%).

Shares of BBOT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/10/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BBOT
CIK
1869105
Fax
N/A
Employees
88
Year Founded
2025

Price Target and Rating

High Price Target
$29.00
Low Price Target
$9.00
Potential Upside/Downside
+852.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.16)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$134.04 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-49.01%
Return on Assets
-43.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.08
Quick Ratio
4.08

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.14 per share
Price / Book
0.39

Miscellaneous

Outstanding Shares
80,251,000
Free Float
60,670,000
Market Cap
$162.91 million
Optionable
N/A
Beta
0.86

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:BBOT) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners